Stock Analysis
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)TAK
Sector: Healthcare · Industry: Drug Manufacturers - General
AnalystsBuy21 analystsPrice is 100% of the way from the year's low to its high.
PMP Verdict
Insufficient financial data
No financial statements on file for this ticker — fundamental scores are not computed.
What's happening with TAK
Risk Flags
- ⚠Interest coverage 0.6× — thin debt cushion
About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4. Show more
5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.
Employees: 47,029 · Website ↗
Price History
Weekly Candlestick Chart — up to 5Y
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
Valuation
50CP/E (TTM)—
Price / TTM EPS (own statements)
P/FCF18.3xB
Grade B: FairPrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield5.5%A
Grade A: ValueInverse of Finnhub P/FCF (own TTM FCF unavailable)
P/S (TTM)2.04xB
Grade B: FairPrice / TTM Revenue (own statements)
EV/EBITDA27.8xD
Grade D: ExpensiveEnterprise value / EBITDA (Finnhub) — capital-structure neutral
EV/Sales3.0xB
Grade B: FairEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E34.5xC
Grade C: ExpensivePrice / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio1.09xA
Grade A: FairPrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio0.50A
Grade A: CheapFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield3.37%A
Grade A: PaysTTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio138.0%D
Grade D: UnsustainableDividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
5EROIC—
NOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE-2.2%D
Grade D: WeakReturn on Equity. Neg. equity = heavy buybacks
ROA-1.1%D
Grade D: WeakReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin-3.5%D
Grade D: LowNet Income / Revenue
Operating Margin—
TTM EBIT / TTM Revenue
Gross Margin65.5%A
Grade A: PremiumGross Profit / Revenue
FCF Margin—
FCF / Revenue
True FCF Margin—
TTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Growth
0ERevenue CAGR—
Compound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR—
Compound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)—
Compound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth—
Analyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth
Dilution (5Y)—
Share count change over 5Y
SBC / Net Income—
Stock-based comp/Net income. >30% = dilution risk
SBC / Revenue—
TTM stock-based comp / TTM Revenue
Financial Health
15EAltman Z-Score—
Bankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio1.14xC
Grade C: OkCurrent Assets/Liabilities
Quick Ratio0.62xC
Grade C: Ok(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage0.6xD
Grade D: RiskyEBIT/Interest. >10 Strong
Debt Repayment—
Years to repay net debt via FCF
Net Debt/EBIT—
Leverage. <2x Low, >4x High
Debt/Equity0.65xA
Grade A: LowDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt—
Cash covers how much of total debt. >1 = could repay all debt from cash
Quality
0EPiotroski F-Score—
Financial strength 0–9. >7 Strong
Beneish M-Score—
Earnings manipulation risk. < -2.22 Safe
FCF Conversion—
FCF / Net Income
Margin Stability—
EBIT margin std deviation. Lower = stable
Capex / Revenue—
TTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.30xD
Grade D: LowRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
Insider Transactions
SEC Form 4 · 8 recordsP/S codes are the directional signal; grants, option exercises and tax withholding carry none. Form 4 doesn't flag 10b5-1 plans — scheduled sales may appear within open-market sells.
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Duprey Lauren Rusckowski Filed | Duprey Lauren Rusckowski | SellOpen market sale | -34535 | |
Plump Andrew Stewart Filed | Plump Andrew Stewart | SellOpen market sale | -116191 | |
Plump Andrew Stewart Filed | Plump Andrew Stewart | SellOpen market sale | -19651 | |
Greenway Nicola Deidre Petal Filed | Greenway Nicola Deidre Petal | SellOpen market sale | -12980 | |
Shannon Elaine Mary Filed | Shannon Elaine Mary | SellOpen market sale | -20363 |
Show 3 more filingsShow fewer filings
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Farajallah Awny Samaan Botros Filed | Farajallah Awny Samaan Botros | SellOpen market sale | -14006 | |
Ibrahim Ramy Riad Ahmed Filed | Ibrahim Ramy Riad Ahmed | SellOpen market sale | -7277 | |
Pacheco Rhonda Janice Filed | Pacheco Rhonda Janice | SellOpen market sale | -16901 |
More metrics — Moat, Per Share, Balance Sheet, MarketHide additional metrics
Moat
0EROIC >12% Years—
Share of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability
Gross Margin (Med.)—
Median annual gross margin across available fiscal years — pricing-power durability
FCF-Positive Years—
Share of completed fiscal years with positive free cash flow
Net Margin Floor—
Weakest annual net margin across completed fiscal years — recession/downcycle resilience
Per Share
EPS (TTM)—
TTM net income per share (Finnhub fallback)
Cash / Share$333.85
Cash & short-term investments per share (Finnhub)
Book Value / Share$4782.57
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt—
Total debt obligations (short + long term)
Cash & Equiv.—
Cash and short-term investments
Net Debt—
Total Debt minus Cash. Negative = Net Cash position
Total Equity—
Shareholders' equity (book value)
Asset / Liability—
Total Assets / Total Liabilities
Market
Market Cap$62.84B
Current Market Capitalization
Beta0.27B
Grade B: DefensivePrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Ratio snapshot Oct 17, 2026
Key Insights: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
TAK is up 1.13% at the last close.
- The stock currently yields 3.4% in dividends.
See how TAK ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all TAK moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Oct 15 | Regular | 19.56 | +2.87% | 2.25 |
| Oct 12 | After-hours | 17.87 | -4.59% | -3.95 |
| Sep 29 | Regular | 18.53 | -1.96% | -2.12 |
Frequently Asked Questions about TAK
What is the current Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) stock price?
TAK is trading at $19.67 at the last market close, up 1.13% on the session. PreMarketPrice tracks TAK pre-market, intraday and after-hours prices.
Is TAK stock a buy right now?
PreMarketPrice's quantitative model rates Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)'s financial health at 15/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is TAK stock overvalued?
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at a trailing P/E of n/a and our valuation score rates it 50/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) report earnings?
No confirmed earnings date is currently scheduled for TAK. The Earnings section lists recent reports and updates as dates are announced.
What sector does Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) operate in?
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) operates in the Healthcare sector, within the Drug Manufacturers - General industry. The Related Stocks section lists sector peers for comparison.
What does Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) do?
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.
About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Stock
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) is a US-listed stock operating in the Healthcare sector, specifically the Drug Manufacturers - General industry. As of the latest update, Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is trading at $19.67, up 1.13% on the day with a market capitalization of $62.8 billion. The financial health score for TAK is 15/100, which indicates poor financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for TAK stock.
TAK Stock Analysis & Key Metrics
On PreMarketPrice, you can track Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) across multiple dimensions:
- Pre-market price & movement: Real-time TAK stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for TAK with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) across multiple reporting periods.
- Financial health score: A composite score of 15/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for TAK.
- Sector peers: Compare TAK against 4 other healthcare stocks on key financial metrics.
Is TAK a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) as an investment. The financial health score of 15/100 suggests poor financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.